

APPENDIX 4E – PRELIMINARY FINANCIAL REPORT

PERTH, Australia and SAN FRANCISCO, California – 28 August 2025

PYC Therapeutics (ASX: PYC) submits the following Appendix 4E – Preliminary Financial Report for the year ended 30 June 2025.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development ¹.

For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [X](#).

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact

investor@pyctx.com



¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

1. Company details

Name of entity:	PYC Therapeutics Limited
ABN:	48 098 391 961
Reporting period:	For the year ended 30 June 2025
Previous period:	For the year ended 30 June 2024

2. Results for announcement to the market

				\$
Income from ordinary activities	Up	14.5%	to	26,171,233
Loss from ordinary activities after tax attributable to the owners of PYC Therapeutics Limited and its controlled entities	Up	33.3%	to	(50,304,679)
Loss for the year attributable to the owners of PYC Therapeutics Limited and its controlled entities	Up	33.3%	to	(50,304,679)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

For commentary on the results of the Group refer to the FY2025 Annual Report.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	28.56	16.71

The PCP has been calculated using post consolidation ordinary securities.

4. Control gained / or lost over entities

PYC Therapeutics Limited increased its equity share in Vision Pharma Limited during the period ending 30 June 2025 by 0.9% taking its ownership stake to 97.1%.

5. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

6. Dividend reinvestment plans

Not applicable.

7. Details of associates and joint venture entities

Name of associate / joint venture	Reporting entity's percentage holding		Contribution to profit/(loss) (where material)	
	Reporting period %	Previous period %	Reporting period \$	Previous period \$
Murdoch University Collaborations (no material contribution to profit/(loss))	-	50%	-	-
Group's aggregate share of associates and joint venture entities' profit/(loss) (where material)				
Profit/(loss) from ordinary activities before income tax			-	-

The above collaboration ceased during the period ending 30 June 2025

8. Foreign entities

The financial statements have been prepared in accordance with the Australian Accounting Standards as issued by the Australian Accounting Standards Board, the Corporations Act 2001 and other mandatory professional reporting requirements.

9. Audit qualification or review

The financial statements have been audited by the Group's independent auditor who have included a paragraph regarding a material uncertainty in relation to going concern in their report.

Signed



Dr Rohan Hockings

Executive Director & Chief Executive Officer – Perth

Date: 28 August 2025